Ameriprise Financial Inc. Sells 244,102 Shares of Repligen Corporation $RGEN

Key Points

• Ameriprise Financial Inc. has reduced its stake in Repligen Corporation by 26.3%, now holding approximately $87.16 million worth of shares after selling over 244,000 shares in the first quarter.
• After reporting quarterly earnings, Repligen missed profit expectations but achieved a revenue of $182.37 million, exceeding estimates of $174.62 million and showing a 14.8% increase from the previous year.
• Analyst ratings are mixed, with Wells Fargo lowering its target price while Royal Bank of Canada increased theirs, reflecting varying confidence in Repligen's stock performance.

Ameriprise Financial Inc. trimmed its position in Repligen Corporation (NASDAQ:RGEN - Free Report) by 26.3% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 684,988 shares of the biotechnology company's stock after selling 244,102 shares during the period. Ameriprise Financial Inc. owned approximately 1.22% of Repligen worth $87,160,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Alliance Wealth Advisors LLC UT increased its holdings in shares of Repligen by 2.5% in the first quarter. Alliance Wealth Advisors LLC UT now owns 3,675 shares of the biotechnology company's stock valued at $468,000 after buying an additional 89 shares in the last quarter. Utah Retirement Systems increased its holdings in shares of Repligen by 1.1% in the fourth quarter. Utah Retirement Systems now owns 9,294 shares of the biotechnology company's stock valued at $1,338,000 after buying an additional 100 shares in the last quarter. State of Michigan Retirement System increased its holdings in shares of Repligen by 0.8% in the first quarter. State of Michigan Retirement System now owns 12,453 shares of the biotechnology company's stock valued at $1,585,000 after buying an additional 100 shares in the last quarter. Louisiana State Employees Retirement System raised its stake in Repligen by 0.7% during the 1st quarter. Louisiana State Employees Retirement System now owns 14,600 shares of the biotechnology company's stock valued at $1,858,000 after purchasing an additional 100 shares during the period. Finally, Signaturefd LLC raised its stake in Repligen by 65.3% during the 1st quarter. Signaturefd LLC now owns 324 shares of the biotechnology company's stock valued at $41,000 after purchasing an additional 128 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Stephens raised shares of Repligen to an "overweight" rating and set a $160.00 target price on the stock in a research note on Tuesday, July 22nd. Evercore ISI cut their target price on shares of Repligen from $140.00 to $130.00 and set an "in-line" rating on the stock in a research note on Tuesday, July 8th. HC Wainwright reissued a "buy" rating and set a $180.00 target price on shares of Repligen in a research note on Monday, May 5th. Wells Fargo & Company cut their target price on shares of Repligen from $180.00 to $175.00 and set an "overweight" rating on the stock in a research note on Wednesday, July 30th. Finally, Wall Street Zen downgraded shares of Repligen from a "buy" rating to a "hold" rating in a research note on Sunday, June 29th. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, Repligen currently has an average rating of "Moderate Buy" and an average price target of $169.45.

Insider Activity at Repligen

In related news, Director Martin D. Madaus purchased 1,800 shares of the stock in a transaction dated Friday, August 8th. The shares were acquired at an average cost of $112.13 per share, for a total transaction of $201,834.00. Following the acquisition, the director directly owned 1,800 shares in the company, valued at approximately $201,834. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.20% of the stock is currently owned by corporate insiders.

Repligen Stock Up 0.1%

Shares of Repligen stock traded up $0.15 on Friday, hitting $122.32. 651,937 shares of the company traded hands, compared to its average volume of 722,374. The company has a 50-day moving average price of $121.74 and a 200 day moving average price of $130.10. The company has a quick ratio of 7.32, a current ratio of 8.59 and a debt-to-equity ratio of 0.26. Repligen Corporation has a 12-month low of $102.96 and a 12-month high of $182.52. The company has a market cap of $6.88 billion, a PE ratio of -489.26, a PEG ratio of 2.25 and a beta of 1.07.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 EPS for the quarter, missing the consensus estimate of $0.40 by ($0.03). Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The company had revenue of $182.37 million for the quarter, compared to analysts' expectations of $174.62 million. During the same quarter in the prior year, the firm earned $0.40 earnings per share. The company's revenue was up 14.8% on a year-over-year basis. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. Sell-side analysts predict that Repligen Corporation will post 1.72 earnings per share for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.